---
title: "Xilio soars after tie-up with AbbVie to develop cancer treatments"
date: "2025-02-12 23:52:44"
summary: "** Shares of drug developer Xilio Therapeutics more than double to $1.49, set for record single-day pct gain** AbbVie and XLO enter into collaboration and option agreement to develop cancer immunotherapies** Under terms of the deal, XLO to receive $52 million in an upfront payment and will be eligible to..."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

\*\* Shares of drug developer Xilio Therapeutics more than double to $1.49, set for record single-day pct gain

\*\* AbbVie and XLO enter into collaboration and option agreement to develop cancer immunotherapies

\*\* Under terms of the deal, XLO to receive $52 million in an upfront payment and will be eligible to receive up to about $2.1 billion in milestone payments

\*\* Deal gives ABBV access to XLO's proprietary tumor-activation technology to develop new immunotherapies

\*\* More than ~84 mln shares traded, 234 times their 25-day moving average

\*\* In the last 12 months, XLO has fallen 7%

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L4N3P31E9:0-xilio-soars-after-tie-up-with-abbvie-to-develop-cancer-treatments/)
